Erasca, Inc.
erasca.comWhat Do They Do?
Develops experimental cancer medicines for patients whose tumors are driven by particular cell-signaling changes.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$44.1MView ↗
- ▲ +30% (Loss)
- vs −$33.9M in Q2 FY2025
Portfolio focus
The older report described candidates against several cancer cell signals, while the latest centers its clinical work on medicines targeting RAS and KRAS, retains an EGFR antibody in discovery, and says it stopped developing naporafenib.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 12, 2026Our modality-agnostic approach aims to allow us to selectively and potently inhibit or degrade critical signaling nodes with small molecule…View ↗
Target upstream and downstream MAPK pathway nodes with single agents and combinations intended to clamp these oncogenic drivers. Our lead…View ↗
Target RAS, the midstream MAPK pathway node, directly with single agents and combinations. We are discovering and developing molecules that…View ↗
Who Do They Compete With?
Competes with Adlai Nortye, Amgen, Boehringer Ingelheim, BridgeBio Oncology Therapeutics, Bristol Myers Squibb, Eli Lilly, GenFleet Therapeutics, Jacobio Pharmaceuticals, Merck, Pfizer, Revolution Medicines, and Roche/Genentech
10-K for FY2025, filed Mar 12, 2026There are numerous companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology…View ↗
Loading...
